The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 g/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC 50 and MIC 90 values for ceftolozane-tazobactam were 0.5 g/ml and 1 g/ml, respectively (a 32-fold-lower MIC 90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by <8 g/ml of ceftolozane-tazobactam.
The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 g/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC 50 and MIC 90 values for ceftolozane-tazobactam were 0.5 g/ml and 1 g/ml, respectively (a 32-fold-lower MIC 90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by <8 g/ml of ceftolozane-tazobactam. P seudomonas aeruginosa is an important cause of nosocomial bloodstream, respiratory, urinary tract, and wound infections (1) (2) (3) (4) . Clinical isolates of P. aeruginosa may demonstrate resistance to multiple classes of antimicrobials, leaving clinicians with few therapeutic options from which to choose (5) . Not surprisingly, multidrug resistance among P. aeruginosa has been associated with adverse clinical outcomes, including increased mortality (6) (7) (8) (9) . Of concern, there are few novel antimicrobials on the horizon with significant in vitro activity versus P. aeruginosa (10) .
Ceftolozane (formerly CXA-101) is a novel antibacterial currently under development that could prove useful in the treatment of infections caused by multidrug-resistant (MDR) P. aeruginosa (11) (12) (13) . Resistance to ␤-lactams among P. aeruginosa strains may be mediated by the overproduction of an AmpC ␤-lactamase, reduction in cell permeability (OprD loss), upregulation of efflux pumps, and/or the acquisition of extended-spectrum or metallo-␤-lactamases (14) . Ceftolozane demonstrates low affinity for the AmpC ␤-lactamase of P. aeruginosa and improved binding to P. aeruginosa penicillin-binding proteins relative to ceftazidime (15, 16) . Furthermore, the in vitro activity of ceftolozane does not appear to be significantly compromised by common efflux pumps found in P. aeruginosa or by reduced permeability related to OprD loss (17) . The purpose of this study was to evaluate the in vitro activity of ceftolozane in combination with tazobactam against P. aeruginosa clinical isolates obtained from patients in Canadian hospitals.
Between 2007 and 2012, 10 to 15 tertiary care medical centers (depending on the study year) representing 8 of the 10 Canadian provinces submitted pathogens from patients attending hospital clinics, emergency rooms, medical and surgical wards, and intensive care units (CANWARD Study). The sites were geographically distributed in a population-based fashion. Annually, each study site was asked to submit clinical isolates (consecutively, one per patient per infection site) from inpatients and outpatients with bloodstream, respiratory, urine, and wound or intravenous (i.v.) infections. The medical centers submitted clinically significant isolates, as defined by their local site criteria. Isolate identification was performed by the submitting site and confirmed at the reference site as required (i.e., when morphological characteristics and antimicrobial susceptibility patterns did not fit the re-ported identification). Isolates were shipped on Amies semisolid transport medium to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada), subcultured onto the appropriate medium, and stocked in skim milk at Ϫ80°C until MIC testing was carried out.
Following 2 subcultures from frozen stock, the in vitro activities of commonly used antipseudomonal antimicrobials were determined by broth microdilution in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines (18, 19) . For testing of ceftolozane-tazobactam, doubling concentrations of ceftolozane were evaluated in combination with a fixed concentration of tazobactam (4 g/ml). Antimicrobial MIC interpretive standards were defined according to CLSI breakpoints (18) . At present, no breakpoints have been set for the combination ceftolozane-tazobactam. MDR P. aeruginosa isolates were defined as those isolates demonstrating resistance to at least one antimicrobial from 3 or more different classes. For the purpose of this report, the five antimicrobial classes considered were aminoglycosides (tobramycin), fluoroquinolones (ciprofloxacin), antipseudomonal cephalosporins (ceftazidime), antipseudomonal penicillins (piperacillintazobactam), and carbapenems (meropenem). Colistin was not used in the classification of MDR isolates.
In total, 2,435 P. aeruginosa isolates were obtained as part of the CANWARD Study, grouped as follows: (i) by year, 623 from 2007, 373 from 2008, 470 from 2009, 376 from 2010, 329 from 2011, and 264 from 2012; (ii) by specimen source, 61.6% respiratory, 21.3% blood, 11.4% wound, and 5.7% urine; and (iii) by ward type, 32.1% medical, 25.2% clinics, 21.9% intensive care units (ICUs), 13.0% emergency rooms (ERs), and 7.8% surgical. The antimicrobial susceptibility profile of these isolates is presented in Table 1 . Ceftolozane-tazobactam demonstrated the lowest MIC 90 value of all antipseudomonal antimicrobials evaluated, including colistin.
The in vitro activity of ceftolozane-tazobactam against P. aeruginosa isolates susceptible or nonsusceptible to various antimicrobials is presented in Table 2 .
One hundred fifty-eight isolates (6.5%) were MDR. The MIC 50 and MIC 90 values for ceftolozane-tazobactam and ceftazidime versus the MDR isolates were 2 g/ml and 16 g/ml, and Ͼ32 g/ml and Ͼ32 g/ml, respectively ( Table 1 ). The most common MDR phenotypes were resistance to ceftazidime, piperacillin-tazobactam, and meropenem (phenotype 1; n ϭ 35), resistance to meropenem, tobramycin, and ciprofloxacin (phenotype 2; n ϭ 25), and resistance to ceftazidime, piperacillin-tazobactam, meropenem, and ciprofloxacin (phenotype 3; n ϭ 21). The ceftolozanetazobactam MIC 50 and MIC 90 values for MDR isolates demonstrating resistance phenotypes 1, 2, and 3 were 2 and 8 g/ml, 1 and 2 g/ml, and 2 and 4 g/ml, respectively.
Previously published studies have demonstrated excellent in vitro activity of ceftolozane, with or without tazobactam, against P. aeruginosa. In general, MIC 90 values for ceftolozane-tazobac- tam have been reported to be 8-to 16-fold lower than those for ceftazidime, irrespective of whether ceftazidime-susceptible or ceftazidime-resistant isolates were evaluated (11, 20) . The data presented here are in agreement with these results. This report serves to expand on the previous literature by providing further evaluation of ceftolozane-tazobactam versus a random collection of P. aeruginosa clinical isolates obtained across a large geographic area (the country Canada). There are several limitations to this study that deserve attention. Ceftolozane was not tested in the absence of tazobactam, because of limited space on the antimicrobial susceptibility panels. Hence, the value of adding tazobactam to ceftolozane could not be ascertained from these data. Previous publications suggest that the contribution of tazobactam to the activity of ceftolozane against P. aeruginosa, if any, is minimal (11, 20) . The mechanisms conferring resistance to the antipseudomonal antimicrobials evaluated here were also not investigated.
In summary, the combination of ceftolozane and tazobactam demonstrated excellent in vitro activity (low MIC 50 and MIC 90 values) against a large collection of 2,435 P. aeruginosa clinical isolates obtained from across Canada. The MIC 90 value for the combination ceftolozane-tazobactam was 32-fold lower than that for ceftazidime. Furthermore, 89.2% of MDR P. aeruginosa isolates were inhibited by Յ8 g/ml of ceftolozane-tazobactam (Table 2). These in vitro data suggest that ceftolozane-tazobactam may prove useful in the future treatment of infections caused by P. aeruginosa, including MDR strains resistant to piperacillin-tazobactam, antipseudomonal cephalosporins, and carbapenems.
(These data were presented in part at IDWeek, San Diego, CA, 17 to 21 October 2012.)
